BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29855074)

  • 1. Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.
    Hendijani F; Azarpira N; Kaviani M
    Clin Transplant; 2018 Aug; 32(8):e13306. PubMed ID: 29855074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
    Khan AR; Raza A; Firasat S; Abid A
    Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
    Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
    Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of
    Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.
    Pasari AS; Balwani MR; Gurjar P; Bawankule C; Bhawane A; Tolani P; Kashiv P; Dubey S; Katekhaye VM
    Transplant Proc; 2023 Jun; 55(5):1305-1309. PubMed ID: 36973144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.
    Rojas LE; Herrero MJ; Bosó V; García-Eliz M; Poveda JL; Librero J; Aliño SF
    Pharmacogenet Genomics; 2013 Oct; 23(10):509-17. PubMed ID: 23873120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.